SCHEMBL5833331

SCHEMBL5833331

O=Cc1cc2ccncc2n1S(=O)(=O)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.43
HTR6 P50406 6/20 0.42
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
CXCL8 P10145 1/20 0.40
NOD1 Q9Y239 1/20 0.40
NAMPT P43490 1/20 0.39
SRC P12931 1/20 0.38
CA12 O43570 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
HDAC3 O15379 2/20 0.36
HDAC4 P56524 2/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC7 Q8WUI4 2/20 0.36
HDAC2 Q92769 2/20 0.36
HDAC10 Q969S8 2/20 0.36
HDAC11 Q96DB2 2/20 0.36
HDAC8 Q9BY41 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10553405 0.89 RECQL (0.43) RECQLHTR6ALDH1A1LMNAMAPT
SCHEMBL369194 0.83 CA12 (0.52) RECQLHTR6ALDH1A1LMNAMAPT
SCHEMBL30276218 0.83 CA12 (0.52) RECQLHTR6ALDH1A1LMNAMAPT
SCHEMBL21115189 0.81 HTR6 (0.44) RECQLHTR6ALDH1A1LMNAMAPT
SCHEMBL4271243 0.78 RECQL (0.57) RECQLHTR6ALDH1A1LMNAMAPT
SCHEMBL5833077 0.77 PPARG (0.44) RECQLHTR6ALDH1A1LMNAMAPT
SCHEMBL4276540 0.77 RECQL (0.56) RECQLHTR6ALDH1A1LMNAMAPT
SCHEMBL20853109 0.77 PTGDR2 (0.42) RECQLHTR6ALDH1A1LMNAMAPT
SCHEMBL17433427 0.77 LMNA (0.40) RECQLHTR6ALDH1A1LMNAMAPT
SCHEMBL4035724 0.76 ALDH1A1 (0.52) RECQLHTR6ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10039755-B2 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors GLAXO GROUP LIMITED (GB) 2018-08-07 US disclosed
US-10039755-B2 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors GLAXO GROUP LIMITED (GB) 2018-08-07 US disclosed
US-20180161316-A1 2-(AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS GLAXO GROUP LIMITED (GB) 2018-06-14 US disclosed
US-20180161316-A1 2-(AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS GLAXO GROUP LIMITED (GB) 2018-06-14 US disclosed
US-9833449-B2 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors GLAXO GROUP LIMITED (GB) 2017-12-05 US disclosed
US-9833449-B2 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors GLAXO GROUP LIMITED (GB) 2017-12-05 US disclosed
US-20170119750-A1 2- (AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS GLAXO GROUP LIMITED (GB) 2017-05-04 US disclosed
US-20170119750-A1 2- (AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS GLAXO GROUP LIMITED (GB) 2017-05-04 US disclosed
US-20170119750-A1 2- (AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS GLAXO GROUP LIMITED (GB) 2017-05-04 US disclosed
US-9518054-B2 2-(azaindol-2-yl) benz imidazoles as PAD4 inhibitors GLAXO GROUP LIMITED (GB) 2016-12-13 US disclosed
US-9127003-B2 2-(azaindol-2-yl)benzimidazoles as PAD4 inhibitors GLAXO GROUP LIMITED (GB) 2015-09-08 US disclosed
US-9127003-B2 2-(azaindol-2-yl)benzimidazoles as PAD4 inhibitors GLAXO GROUP LIMITED (GB) 2015-09-08 US disclosed
US-20150175600-A1 2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS Glaxo Group Limited a corporation 2015-06-25 US disclosed
US-20150175600-A1 2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS Glaxo Group Limited a corporation 2015-06-25 US disclosed
US-20150175600-A1 2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS Glaxo Group Limited a corporation 2015-06-25 US disclosed
EP-2877467-A1 2 - (AZAINDOL- 2 -YL) BENZ IMIDAZOLES AS PAD4 INHIBITORS Glaxo Group Limited (GB) 2015-06-03 EP disclosed
CN-104470919-A 2 - (azaindol- 2 -yl) benz imidazoles as pad4 inhibitors GLAXO GROUP LTD 2015-03-25 CN disclosed
WO-2014015905-A1 2 - (AZAINDOL- 2 -YL) BENZ IMIDAZOLES AS PAD4 INHIBITORS GLAXO GROUP LIMITED (GB) 2014-01-30 WO disclosed
EP-1732566-A2 6-AZAINDOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2006-12-20 EP disclosed
WO-2005097129-A2 6-AZAINDOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10039755-B2 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors PADI1, PADI4, PADI2 RECQL 476/4885HTR6 2651/4885ALDH1A1 98/4885
US-20150175600-A1 2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS PADI1, PADI4, PADI2 RECQL 390/4885HTR6 2505/4885ALDH1A1 77/4885
US-20180161316-A1 2-(AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS PADI1, PADI4, PADI2 RECQL 490/4885HTR6 2600/4885ALDH1A1 107/4885
US-20170119750-A1 2- (AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS PADI1, PADI4, PADI2 RECQL 390/4885HTR6 2517/4885ALDH1A1 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.